Introduction
HIV-1 infects and replicates in CD4 þ T cells and in cells of the monocyte/macrophage lineage using CD4 molecule and the chemokine receptors, CXCR4 or CCR5, to penetrate into host cells [1] . A variety of cytokines and endogenous soluble factors have been shown to modulate HIV-1 replication during the course of the disease [2] [3] [4] [5] . Slits are a group of large secreted glycoproteins originally described in regulating neural migration [6, 7] . Slit consists of a family of three genes: Slit1, Slit2 and Slit3, all of which are expressed in the nervous system. However, Slit2 and Slit3 can also be found in several nonneuronal tissues. Robo1, the predominant receptor for Slit2 belongs to a novel subfamily of immunoglobulin superfamily proteins [8, 9] and is also expressed in several nonneuronal tissues, including leukocytes. However, information on the effects of Slit2/Robo1 axis in nonneuronal systems is still fragmentary, with recent studies indicating its role in multiple processes including tumor growth and metastasis [10] [11] [12] [13] [14] . With regard to the immune system, Slit2 was shown to decrease inflammation and disease progression in animal models of global ischemia [15] , crescentic glomerulonephritis [16] and sepsis [17] . Slit2 has been shown to inhibit migration of various immune cells toward chemoattractant signals [18] [19] [20] [21] [22] . Specifically, we and others have recently shown Slit2 blocks CXCL12/ CXCR4-mediated functional effects in T cells [22, 23] . The chemokine receptors, CXCR4, along with CCR5, are important coreceptors for HIV-1 virus.
In the present study, we analyzed the role of Slit2 in HIV-1 replication. We demonstrate, for the first time, that endogenously expressed Slit2 in T cells modulates HIV-1 replication. Furthermore, we demonstrate that soluble Slit2 upon binding to Robo1 receptor modulates both X4-tropic and R5-tropic HIV-1 replication in T-cell lines and peripheral blood mononuclear cells (PBMCs).
Methods
Anti-HIV-1 assays PBMCs were isolated from heparinized venous blood collected from healthy HIV-seronegative donors (American Red Cross, Columbus, Ohio, USA) as described before [20] . The viral isolates, HIV-1 IIIB, BaL, JRFL, HxBc2 and NL4-3, were obtained from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program.
The T-cell line, MT4, was pretreated with various concentrations of Slit2 and infected with HIV-1 IIIB (p24 10 ng per 10 6 cells), washed extensively after 2 h of infection to remove the residual virus and incubated for 48 h. Phytohemagglutinin (PHA)-stimulated PBMCs pretreated with Slit2 were infected similarly with HIV-1. However, PBMCs [in interleukin (IL-2)-containing complete Roswell Park Memorial Institute (RPMI)] were incubated for up to 2 weeks. Every 3-4 days, half the cell suspension was removed and replaced with fresh medium containing the same concentration of Slit2. HIV-1 p24 antigen levels in the culture supernatant were assessed by ELISA (Advanced Bioscience Laboratories, Rockville, Maryland, USA).
Immunostaining and flow cytometry
To determine intracellular p24 expression, HIV-1infected T cells were fixed and permeabilized using Fix/perm solution (BD Biosciences, San Diego, California, USA) and stained with KC57 monoclonal antibody (Coulter, Brea, California, USA). Robo1 receptor was analyzed by flow cytometry using Robo-1 antibodies (Abcam, Cambridge, Massachusetts, USA) or control antibody, as described previously [20] .
Soluble Slit2 production HEK293 cells that produce full-length myc-tagged Slit2 proteins have been described [22] . Slit2 and vector controlconditioned media were concentrated and partially purified according to procedures described previously [20] . For our initial studies, we used partially purified conditioned media from Slit2/myc-transfected HEK293 cells at a concentration of approximately 6-15 nmol/l. The concentration of Slit2 in the conditioned medium was estimated based on silver staining of serial dilutions of supernatants following SDS-PAGE fractionation ( Fig. S1 , http://links.lww.com/QAD/A176). Conditioned medium from vector-transfected HEK293 cells at similar amounts were used as controls. These concentrations of Slit2-conditioned media have been described in various studies to analyze the functional effects of Slit2 [19] [20] [21] 24] .
For further studies, Slit2 in the conditioned medium was purified, as described previously [20] . The fractions were analyzed on 8% SDS-PAGE gels, stained with silver stain or on immunoblots and probed with anti-myc antibodies. The fractions containing Slit2 were dialyzed with PBS, concentrated and used for the HIV-1 replication assays.
Transfections
The pSecTagB-Slit2 construct [12] or control pSecTagB vector were transfected onto T-cell lines and primary cells using Nucleofector V or T solution (Amaxa Biosystems, Cologne, Germany) according to the manufacturer's instructions. Small inhibitor RNA (siRNA)-mediated knockdown of Robo-1 and Slit2 was performed using specific ON-TARGETplus SMARTpool siRNA (Dharmacon Lafayette, Colorado, USA.) by nucleofection with 200 nmol/l siRNA. The respective, nontargeted siRNA was used as a control.
Western blot analysis
Cell lysates were subjected to western blot analysis, as previously described [20] .
Statistical analysis
Reported data are the means AE SD of at least three independent experiments performed in duplicate or triplicate. The statistical significance was determined by the Student's t-test.
Results

Endogenous Slit2 regulates HIV-1 replication in T cells
We have previously shown that Slit2 modulates CXCR4mediated functional effects in T cells [20] . As CXCR4 also acts as a coreceptor for HIV-1, we investigated the role of Slit2 in modulating HIV-1 replication. Analysis of Slit2 expression in Jurkat T cells and MT4 cells revealed that Jurkat T cells expressed higher amount of Slit2 compared with MT4 cells (Fig. 1a , left panel). We also demonstrated Slit2 expression in PBMCs from normal donors ( Fig. 1a, right Jur.
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Jur. T cells using Slit2-specific siRNA on HIV-1 replication (Fig. 1b, left panel) . We observed that downregulation of constitutive Slit2 enhanced HIV-1 replication in Jurkat T cells by approximately 1.6-fold ( Fig. 1b, right panel) .
Slit2
To further confirm the role of Slit2 in HIV infection, we overexpressed Slit2 in MT4 cells and PBMCs by transfecting pSecTagB-Slit2 construct [12] or pSecTagB control vector in these cells. The efficiency of the transfection was confirmed by determining Slit2 expression in cell lysates by western blot analysis (Fig. 1c, left top  panel) . We also observed Slit2 protein in the supernatants of T cells after Slit2 overexpression (Fig. 1c, bottom  panel) , indicating that overexpression results in Slit2 secretion. The Slit2-transfected MT4 cells showed approximately two-fold inhibition of HIV-1 replication (Fig. 1c, right panel) , whereas the Slit2-transfected PBMCs showed an inhibition of approximately 3.5-fold using HIV-1 IIIB (Fig. 1d, left panel) and approximately two-fold using HIV-1 BaL (Fig. 1d, right panel) in comparison with vector-transfected cells, suggesting that overexpression of Slit2 in T cells was protective against HIV-1 infection. Together, these studies indicate that endogenously expressed Slit2 in T cells may play an important role in regulating HIV-1 infection.
Soluble Slit2 suppresses both X4-tropic and R5-tropic HIV-1 replication
As Slit2 is a secretory protein, we further determined whether soluble Slit2 would block HIV replication. Initially, we evaluated the effect of soluble Slit2 on HIV-1 replication using partially purified Slit2-conditioned medium or equal amounts of vector control-conditioned medium. Slit2 expression was detected in the conditioned medium by western blotting with anti-myc ( Fig. 2a , left panel) or anti-Slit2 antibody (data not shown). Slit2conditioned medium showed approximately five-fold inhibition of viral replication in MT4 cells at the end of 48 h as compared with the control (Fig. 2a, middle panel) . We next showed that Slit2-conditioned medium also resulted in approximately two-fold inhibition of HIV-1 IIIB replication in PBMCs at 7-14 days in comparison to the control (Fig. 2a, right panel) . Furthermore, we determined the anti-HIV activity of a highly purified form of Slit2 (Fig. 2b, left panel) prepared according to our published studies [23] . Purified Slit2 showed a dose-dependent inhibition of HIV-1 IIIB replication in MT4 cells with approximately five-fold reduction in HIV-1 replication at 6-nmol/l Slit2 (Fig. 2b, middle  panel) . Purified Slit2 also inhibited HIV-1 IIIB replication in PBMCs, with an inhibition of approximately three-fold to four-fold at 4-14 days (Fig. 2b, right panel) .
In addition, we evaluated other HIV-1 X4 isolates, HxBc2 and NL4-3, and found similar inhibition of HIV-1 replication (data not shown).
We next addressed the question whether Slit2 also modulates replication of R5-tropic strains. We observed that Slit2-conditioned medium (Fig. 2c, left panel) or purified Slit2 in a dose-dependent manner (Fig. 2c , right panel) inhibited HIV-1 BaL viral replication in PBMCs. Our findings were also confirmed using other R5-tropic strains including JRFL and YU2 (data not shown). Furthermore, we also confirmed the anti-HIV activity of both the Slit2-conditioned supernatant and purified Slit2 on CD4 þ T cells isolated from PBMCs (Fig. S2 , http://links.lww.com/QAD/A176). In all experiments, we found no significant difference in cell growth and viability in uninfected cells in the presence and absence of Slit2 (Fig. S3 , http://links.lww.com/QAD/A176). The above results, thus, confirm that Slit2 can inhibit HIV-1 replication independent of viral tropism and of the cell type used to produce virus.
Anti-HIV activity of Slit2 is mediated through Robo1
Slit2 has been shown to mediate its effects by binding to Robo1 receptor [6, 8, 9, 20, 22, [24] [25] [26] [27] [28] [29] [30] . We found that Robo1 is expressed on MT4, Jurkat T cells and PBMCs using western blot analysis and flow cytometry (data not shown). Next, we determined whether Slit2-mediated anti-HIVeffects are mediated through Robo1. MT4 cells transfected with Robo1 siRNA showed a significant knockdown of Robo1 expression as compared with nontargeted siRNA transfected cells (Fig. 2d, left panel) . As shown in Fig. 2d , right panel, Robo1 downregulation abrogated Slit2-mediated inhibitory effects compared with control, suggesting that the anti-HIVactivity of Slit2 is predominantly transduced by Robo1.
Discussion
Slit2 has recently been shown to modulate CXCR4mediated functional effects and possess anti-inflammatory properties. However, nothing is known about its role in HIV pathogenesis. In the present study, we provide the evidence, for the first time, linking Slit2 to modulation of HIV-1 replication, thus adding a new dimension to the biological functions to Slit2.
We demonstrated Slit2 expression in both T-cell lines and PBMCs. The expression of endogenous Slit2 and its function in leukocytes has not been studied previously.
Our studies indicate that Slit2 overexpression inhibited HIV-1 replication in MT4 and PBMCs, whereas inhibition of constitutive Slit2 expression in Jurkat T cells slightly enhanced HIV-1 replication, suggesting that endogenous Slit2 expression and secretion may modulate HIV-1 replication in T cells probably by acting in an autocrine/paracrine manner. We also showed that soluble Slit2 inhibited both X4-tropic and R5-tropic HIV-1 using both partially purified Slit2-conditioned medium and purified Slit2. Several factors expressed by host cells, including APOBEC3G/F, TRIM5a, CD317 and Murr1 [31] [32] [33] [34] as well as soluble mediators such as IL-10, IL-27 and type 1 interferon, have also been shown to inhibit HIV-1 replication [2] [3] [4] [5] . We propose that Slit2 could be a novel soluble factor expressed by host cells that may modulate HIV-1 replication. Our finding that Slit2 may modulate HIV-1 replication by binding to Robo1 receptor is in agreement with various recent studies that have shown that Slit2 binds to Robo1 to mediate many of its functional effects [35] [36] [37] . Our preliminary studies indicated that Slit2 did not affect HIV receptor/coreceptor expression in T cells (data not shown). We have previously shown that Slit2 modulates CXCL12/CXCR4 signaling by inhibiting Akt and Rac1 activation [20] , both of which have been shown to play an important role in mediating HIV entry [38, 39] . We, therefore, hypothesize that Slit2 may inhibit HIV by modulating signaling pathways that mediate viral entry.
Conclusion
Overall, our studies demonstrate a novel role for Slit2/ Robo1 axis in HIVreplication and may contribute to the understanding of HIV-1 pathogenesis.
